Elkedonia

French tech company | Builders Republic

About

Clinical-stage biotech developing a new class of antidepressants for treatment-resistant depression and other neuropsychiatric disorders — built on compounds that promote rewiring of neural connections in the brain, with a lead program targeting an intracellular protein involved in mood regulation. Spun out of the Argobio biotech studio.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Seed
Founded
2025
City
STRASBOURG
Region
Grand Est
Tracked rounds
1
Amount raised
11 M€ raised since 2020

Funding rounds

  • Seed — 2025

Investors